|
1
|
Xing M, Haugen BR and Schlumberger M:
Progress in molecular-based management of differentiated thyroid
cancer. Lancet. 381:1058–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang C, Lu S, Jiang J, Jia X, Dong X and
Bu P: Hsa-microRNA-101 suppresses migration and invasion by
targeting Rac1 in thyroid cancer cells. Oncol Lett. 8:1815–1821.
2014.PubMed/NCBI
|
|
3
|
Zhang X, Li M, Zuo K, Li D, Ye M, Ding L,
Cai H, Fu D, Fan Y and Lv Z: Upregulated miR-155 in papillary
thyroid carcinoma promotes tumor growth by targeting APC and
activating Wnt/β-catenin signaling. J Clin Endocrinol Metab.
98:E1305–E1313. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hartmann C, Mueller W and von Deimling A:
Pathology and molecular genetics of oligodendroglial tumors. J Mol
Med (Berl). 82:638–655. 2004. View Article : Google Scholar
|
|
5
|
Geraldo MV, Fuziwara CS, Friguglieti CU,
Costa RB, Kulcsar MA, Yamashita AS and Kimura ET: MicroRNAs
miR-146-5p and let-7f as prognostic tools for aggressive papillary
thyroid carcinoma: A case report. Arq Bras Endocrinol Metabol.
56:552–557. 2012. View Article : Google Scholar
|
|
6
|
Vasko VV and Saji M: Molecular mechanisms
involved in differentiated thyroid cancer invasion and metastasis.
Curr Opin Oncol. 19:11–17. 2007. View Article : Google Scholar
|
|
7
|
Yang Q, Ji M, Guan H, Shi B and Hou P:
Shikonin inhibits thyroid cancer cell growth and invasiveness
through targeting major signaling pathways. J Clin Endocrinol
Metab. 98:E1909–E1917. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang X, Li D, Li M, Ye M, Ding L, Cai H,
Fu D and Lv Z: MicroRNA-146a targets PRKCE to modulate papillary
thyroid tumor development. Int J Cancer. 134:257–267. 2014.
View Article : Google Scholar
|
|
9
|
Lee JC, Gundara JS, Glover A, Serpell J
and Sidhu SB: MicroRNA expression profiles in the management of
papillary thyroid cancer. Oncologist. 19:1141–1147. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rigoutsos I: New tricks for animal
microRNAs: Targeting of amino acid coding regions at conserved and
nonconserved sites. Cancer Res. 69:3245–3248. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li D, Jian W, Wei C, Song H, Gu Y, Luo Y
and Fang L: Down-regulation of miR-181b promotes apoptosis by
targeting CYLD in thyroid papillary cancer. Int J Clin Exp Pathol.
7:7672–7680. 2014.
|
|
14
|
Wu D, Zhou Y, Pan H, Qu P and Zhou J:
MicroRNA99a inhibits cell proliferation, colony formation ability,
migration and invasion by targeting fibroblast growth factor
receptor 3 in prostate cancer. Mol Med Rep. 11:1469–1475. 2015.
|
|
15
|
Pallante P, Battista S, Pierantoni GM and
Fusco A: Deregulation of microRNA expression in thyroid neoplasias.
Nat Rev Endocrinol. 10:88–101. 2014. View Article : Google Scholar
|
|
16
|
Liu B, Peng XC, Zheng XL, Wang J and Qin
YW: MiR-126 restoration down-regulate VEGF and inhibit the growth
of lung cancer cell lines in vitro and in vivo. Lung Cancer.
66:169–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu LY, Wang W, Zhao LY, Guo B, Yang J,
Zhao XG, Hou N, Ni L, Wang AY, Song TS, et al: Mir-126 inhibits
growth of SGC-7901 cells by synergistically targeting the oncogenes
PI3KR2 and Crk, and the tumor suppressor PLK2. Int J Oncol.
45:1257–1265. 2014.PubMed/NCBI
|
|
18
|
Akbari Moqadam F, Boer JM, Lange-Turenhout
EA, Pieters R and den Boer ML: Altered expression of miR-24,
miR-126 and miR-365 does not affect viability of childhood
TCF3-rearranged leukemia cells. Leukemia. 28:1008–1014. 2014.
View Article : Google Scholar
|
|
19
|
Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu
T, Bai Y, Shen Y, Yuan W, Jing Q and Qin Y: Endothelial-specific
intron-derived miR-126 is down-regulated in human breast cancer and
targets both VEGFA and PIK3R2. Mol Cell Biochem. 351:157–164. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Fish JE, Santoro MM, Morton SU, Yu S, Yeh
RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D:
MiR-126 regulates angiogenic signaling and vascular integrity. Dev
Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saito Y, Friedman JM, Chihara Y, Egger G,
Chuang JC and Liang G: Epigenetic therapy upregulates the tumor
suppressor microRNA-126 and its host gene EGFL7 in human cancer
cells. Biochem Biophys Res Commun. 379:726–731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J,
Cai Q, Yan M, Liu B and Zhu Z: MiR-126 functions as a tumour
suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lagos-Quintana M, Rauhut R, Yalcin A,
Meyer J, Lendeckel W and Tuschl T: Identification of
tissue-specific microRNAs from mouse. Curr Biol. 12:735–739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meister J and Schmidt MH: MiR-126 and
miR-126*: New players in cancer. Scientific World Journal.
10:2090–2100. 2010. View Article : Google Scholar
|
|
26
|
Li N, Tang A, Huang S, Li Z, Li X, Shen S,
Ma J and Wang X: MiR-126 suppresses colon cancer cell proliferation
and invasion via inhibiting RhoA/ROCK signaling pathway. Mol Cell
Biochem. 380:107–119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu Q, Liu SL, Wang H, Shi G, Yang P and
Chen XL: MiR-126 suppresses the proliferation of cervical cancer
cells and alters cell sensitivity to the chemotherapeutic drug
bleomycin. Asian Pac J Cancer Prev. 14:6569–6572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jia AY, Castillo-Martin M, Bonal DM,
Sánchez-Carbayo M, Silva JM and Cordon-Cardo C: MicroRNA-126
inhibits invasion in bladder cancer via regulation of ADAM9. Br J
Cancer. 110:2945–2954. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun X, Liu Z, Yang Z, Xiao L, Wang F, He
Y, Su P, Wang J and Jing B: Association of microRNA-126 expression
with clinico-pathological features and the risk of biochemical
recurrence in prostate cancer patients undergoing radical
prostatectomy. Diagn Pathol. 8:2082013. View Article : Google Scholar
|
|
30
|
Zhang J, Du YY, Lin YF, Chen YT, Yang L,
Wang HJ and Ma D: The cell growth suppressor, mir-126, targets
IRS-1. Biochem Biophys Res Commun. 377:136–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y,
Li C, Chong M, Ibrahim T, Mercatali L, et al: MiR-126 and miR-126*
repress recruitment of mesenchymal stem cells and inflammatory
monocytes to inhibit breast cancer metastasis. Nat Cell Biol.
15:284–294. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yarden Y: The EGFR family and its ligands
in human cancer. signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Balkwill FR: The chemokine system and
cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar
|
|
34
|
Wang N, Luo HJ, Yin GB, Dong CR, Xu M,
Chen GG and Liu ZM: Overexpression of HIF-2α, TWIST, and CXCR4 is
associated with lymph node metastasis in papillary thyroid
carcinoma. Clin Dev Immunol. 2013:5894232013. View Article : Google Scholar
|
|
35
|
Oberlin E, Amara A, Bachelerie F, Bessia
C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM,
Clark-Lewis I, Legler DF, et al: The CXC chemokine SDF-1 is the
ligand for LESTR/fusin and prevents infection by
T-cell-line-adapted HIV-1. Nature. 382:833–835. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He X, Wei Q, Zhang X, Xiao J, Jin X, Zhu
Y, Cui B and Ning G: Immunohistochemical expression of CXCR4 in
thyroid carcinomas and thyroid benign lesions. Pathol Res Pract.
206:712–715. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Castellone MD, Guarino V, De Falco V,
Carlomagno F, Basolo F, Faviana P, Kruhoffer M, Orntoft T, Russell
JP, Rothstein JL, et al: Functional expression of the CXCR4
chemokine receptor is induced by RET/PTC oncogenes and is a common
event in human papillary thyroid carcinomas. Oncogene.
23:5958–5967. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Torregrossa L, Giannini R, Borrelli N,
Sensi E, Melillo RM, Leocata P, Materazzi G, Miccoli P, Santoro M
and Basolo F: CXCR4 expression correlates with the degree of tumor
infiltration and BRAF status in papillary thyroid carcinomas. Mod
Pathol. 25:46–55. 2012. View Article : Google Scholar
|
|
39
|
Wagner PL, Moo TA, Arora N, Liu YF,
Zarnegar R, Scognamiglio T and Fahey TJ III: The chemokine
receptors CXCR4 and CCR7 are associated with tumor size and
pathologic indicators of tumor aggressiveness in papillary thyroid
carcinoma. Ann Surg Oncol. 15:2833–2841. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo S, Xiao D, Liu H, Zheng X, Liu L and
Liu S: Interfering with CXCR4 expression inhibits proliferation,
adhesion and migration of breast cancer MDA-MB-231 cells. Oncol
Lett. 8:1557–1562. 2014.PubMed/NCBI
|
